Results 121 to 130 of about 10,275 (197)

Figure 5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

<p>ETx-22 mechanism of action. PDX TNBC400-bearing NSG mice (<i>n</i> = 3 per time point) were injected intravenously when tumors averaged 150 mm³ (T0) with 10 mg/kg of ETx-22 (from humanized 15A7.5 mAb). At the indicated time points, animals were euthanized, and their tumors were collected, measured, and ...
Daniel Olive, Xavier Préville, Jack Elands, François Bertucci, Emilie Mamessier, Florence Lhospice, Hatem A. Azim, Andreas Pahl, Torsten Hechler, Anikó Pálfi, François Romagne, Stéphanie Blanchin, Emmanuelle Charafe, Yves Collette, Maria Wehbe, Joanna Fares, Remy Castellano, Marion Rubis, Anne Farina, Emmanuelle Josselin, Emerence Crompot, Marc Lopez   +21 more
openaire   +1 more source

Figure 1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

<p>Epitope characterization of the 15A7.5 antibody. <b>A,</b> The apparent EC₅₀ ratio of chimeric 15A7.5 and 5A12.2 and human HA22 anti–nectin-4 mAbs on normal differentiated human keratinocytes vs. the SUM190 cell line. <b>B,</b> Specificity of chimeric mAb 15A7.5 for human nectin-4.
Daniel Olive, Xavier Préville, Jack Elands, François Bertucci, Emilie Mamessier, Florence Lhospice, Hatem A. Azim, Andreas Pahl, Torsten Hechler, Anikó Pálfi, François Romagne, Stéphanie Blanchin, Emmanuelle Charafe, Yves Collette, Maria Wehbe, Joanna Fares, Remy Castellano, Marion Rubis, Anne Farina, Emmanuelle Josselin, Emerence Crompot, Marc Lopez   +21 more
openaire   +1 more source

Figure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

<p>Supplementary Figure 3 shows the internalization of 15A7.5 and Ha22</p>
Daniel Olive, Xavier Préville, Jack Elands, François Bertucci, Emilie Mamessier, Florence Lhospice, Hatem A. Azim, Andreas Pahl, Torsten Hechler, Anikó Pálfi, François Romagne, Stéphanie Blanchin, Emmanuelle Charafe, Yves Collette, Maria Wehbe, Joanna Fares, Remy Castellano, Marion Rubis, Anne Farina, Emmanuelle Josselin, Emerence Crompot, Marc Lopez   +21 more
openaire   +1 more source

Figure 6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

<p><i>In vivo</i> efficacy of ETx-22 in SUM190 breast cancer cell line and PDX models. <b>A,</b> NSG mice (<i>n</i> = 5/group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel.
Daniel Olive, Xavier Préville, Jack Elands, François Bertucci, Emilie Mamessier, Florence Lhospice, Hatem A. Azim, Andreas Pahl, Torsten Hechler, Anikó Pálfi, François Romagne, Stéphanie Blanchin, Emmanuelle Charafe, Yves Collette, Maria Wehbe, Joanna Fares, Remy Castellano, Marion Rubis, Anne Farina, Emmanuelle Josselin, Emerence Crompot, Marc Lopez   +21 more
openaire   +1 more source

Figure 4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

<p>PK/PD characterization of ETx-22 ADC. NSG mice and PDX TNBC400-bearing NSG mice (<i>n</i> = 3 per time point) were injected intravenously when tumors averaged 150 mm³ (T0) with 10 mg/kg of ETx-22 (from humanized 15A7.5 mAb).
Daniel Olive, Xavier Préville, Jack Elands, François Bertucci, Emilie Mamessier, Florence Lhospice, Hatem A. Azim, Andreas Pahl, Torsten Hechler, Anikó Pálfi, François Romagne, Stéphanie Blanchin, Emmanuelle Charafe, Yves Collette, Maria Wehbe, Joanna Fares, Remy Castellano, Marion Rubis, Anne Farina, Emmanuelle Josselin, Emerence Crompot, Marc Lopez   +21 more
openaire   +1 more source

Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review. [PDF]

J Nucl Med
Schäfer L, Altunay B, Morgenroth A, Vogg A, Derks Y, Lammers T, Peña Q, Mottaghy FM, Lütje S.   +8 more
europepmc   +1 more source

Aptamēru atlase pret urīnpūšļa audzēja mērķproteīnu Nectin–4 raksturīgiem proteīniem

, 2022
Urīnpūšļa vēzis ir viens no visvairāk diagnosticētajiem vēžiem pasaulē, taču tā diagnostikai un terapijai nepieciešamas jaunas metodes, lai veiksmīgāk atklātu un varētu ārstēt šo slimību. Šo lomu var veikt mērķterapijas zāles, piemēram aptamēri vai antivielas.
openaire   +1 more source

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. [PDF]

Sci Adv
Mishra A, Sharma AK, Gupta K, Banka DS, Johnson BA, Hoffman-Censits J, Huang P, McConkey DJ, Nimmagadda S.   +8 more
europepmc   +1 more source

Figure S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

<p>Supplementary Figure 2 shows IHC analysis of Nectin-4 expression on tumor tissue and human skin keratinocytes using 15A7.5</p>
Daniel Olive, Xavier Préville, Jack Elands, François Bertucci, Emilie Mamessier, Florence Lhospice, Hatem A. Azim, Andreas Pahl, Torsten Hechler, Anikó Pálfi, François Romagne, Stéphanie Blanchin, Emmanuelle Charafe, Yves Collette, Maria Wehbe, Joanna Fares, Remy Castellano, Marion Rubis, Anne Farina, Emmanuelle Josselin, Emerence Crompot, Marc Lopez   +21 more
openaire   +1 more source

Structural basis of nectin-4 recognition by the antibody-drug conjugate 9MW2821. [PDF]

J Biol Chem
Fang P, You M, Wen H, Cao Y, Zhou W, Zhu X, Shi L, Sun X, Li K, Li W, Wang J, Wu H, Tan X.   +12 more
europepmc   +1 more source